Trials / Unknown
UnknownNCT05220124
A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma
An Open Label, Randomized Control Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- Sponsor
- Tianjin Medical University Second Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.
Detailed description
To evaluate the progression free survival of intestinal probiotics in immunotherapy for urothelial carcinoma. Changes in fecal flora abundance before and after treatment were assessed to identify subjects most likely to benefit from enteric probiotics treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) | 420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles. |
Timeline
- Start date
- 2022-01-05
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
- First posted
- 2022-02-02
- Last updated
- 2022-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05220124. Inclusion in this directory is not an endorsement.